Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I/II study of MK-2870 alone or in combination for gastrointestinal tumors
CTR20242869Phase 2Active
- Sponsor
- MSD
- Start
- Oct 2024
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of sacituzumab tirumotecan in gastrointestinal cancer, colorectal adenocarcinoma, pancreatic adenocarcinoma (PDAC), biliary cancer, cholangiocarcinoma (CCA), sponsored by MSD. Started Oct 2024; status: active.
02
Drugs
sacituzumab tirumotecan
03
Conditions
gastrointestinal cancercolorectal adenocarcinomapancreatic adenocarcinoma (PDAC)biliary cancercholangiocarcinoma (CCA)
Beyond the preview
Go deeper on CTR20242869.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20242869.